Skip to main content

Clobetasol Topical Dosage

Medically reviewed by Drugs.com. Last updated on Nov 13, 2023.

Applies to the following strengths: 0.05%; 0.05% with cleanser; 0.05% with emollients; 0.025%

Usual Adult Dose for Dermatitis


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Adult Dose for Eczema


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Adult Dose for Psoriasis


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Adult Dose for Dermatological Disorders


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Adult Dose for Lichen Planus


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Pediatric Dose for Dermatitis


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Pediatric Dose for Eczema


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Pediatric Dose for Psoriasis


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Pediatric Dose for Dermatological Disorders


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Usual Pediatric Dose for Lichen Planus


Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:



Safety and efficacy have not been established in patients younger than 18 years and its use in pediatric patients under 12 years of age is not recommended.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.